Germany-based pharmaceutical major Boehringer Ingelheim has announced the initiation of a long-term collaboration with the Mary Tyler Moore Vision Initiative (MTM Vision), marking the first time a pharmaceutical company has joined the MTM Vision Consortium. This partnership signifies a significant step in collaborative research aimed at addressing vision-related complications of diabetes.
MTM Vision Consortium’s Mission
The MTM Vision Consortium, headquartered at the University of Michigan, is a pioneering initiative designed to bring together innovators from universities, foundations, and pharmaceutical and biotech companies in the pre-competitive space. The consortium’s goal is to foster collaborative efforts that lead to breakthroughs in the prevention and treatment of diabetes-related eye conditions.
Focus on Diabetes Retinopathy
Boehringer Ingelheim’s collaboration with MTM Vision is specifically aimed at leading the charge in vision protection for diabetes patients. The partnership will delve into the complexities of diabetes retinopathy, a leading cause of vision loss among diabetic individuals, and work towards developing innovative drug portfolios to address this critical area of unmet medical need.-Fineline Info & Tech
Leave a Reply